Table 7

Quality of Life and Symptom Assessment in TAVR Trials

Study PopulationNYHA Functional Class6-Minute WalkQuestionnaireOther
PARTNER B (Trial) TAVR vs. placebo (multicenter; N=358) (15,122)More class I, II with TAVR at 1 year (74.8% vs. 42.0%)TAVR improved walk time pre/post at 1 year; no change in no-TAVR groupKCCQ; Marked improvement with TAVR at 1 year; SF12; improvement in physical and mental HRQOL with TAVRTAVR had fewer rehospitalizations at 1 year
PARTNER A (Trial) TAVR vs. SAVR (multicenter; N=699) (124)More class I, II with TAVR at 30 days; No difference between TAVR and SAVR at 1 yearTAVR improved walk time at 30 days compared with SAVR; No difference between TAVR and SAVR at 1 yearNRShorter LOS with TAVR

HRQOL indicates health-related quality of life; KCCQ indicates Kansas City Cardiomyopathy Questionnaire; LOS, length of stay; NR, not reported; QOL, quality of life; SAVR, surgical aortic valve replacement; and TAVR, transcatheter aortic valve replacement.